title: The neuroteratogenicity of procarbazine hydrochloride in the rat: histopathological and immunocytochemical aspects.
abstract: Procarbazine hydrochloride, and antineoplastic drug, was administered to pregnant rats from days 13 to 16 of gestation at doses of 0, 1, 5 and 15 mg per kg as part of a behavioural study. Histological examination of the brains from the offspring at 12 to 15 weeks of age revealed cerebral atrophy, which increased in severity with increasing dose, together with a reduction in neuronal numbers, with no apparent effect upon the astrocyte and oligodendrocyte populations.
authors.affiliation: ICI Pharmaceuticals, Macclesfield, Cheshire, U.K.
authors.forename: J A
authors.initials: JA
authors.lastname: Wright
authors.forename: L
authors.initials: L
authors.lastname: Brickell
authors.forename: J
authors.initials: J
authors.lastname: Foster
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000473:pathology*; D000818:Animals; D001253:Astrocytes / Q000473:pathology; D002540:Cerebral Cortex / Q000002:abnormalities* / Q000473:pathology; D005260:Female; D009474:Neurons / Q000473:pathology; D009836:Oligodendroglia / Q000473:pathology; D011247:Pregnancy; D011344:Procarbazine / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D011344:Procarbazine